CPT® Code 86041

Acetylcholine receptor (AChR) antibodies are specific proteins that can be found in the bloodstream of individuals diagnosed with myasthenia gravis (MG), a rare neuromuscular disorder characterized by muscle weakness and fatigue. Myasthenia gravis can manifest in two primary forms: ocular myasthenia gravis, which primarily affects the eye muscles, leading to symptoms such as drooping eyelids and double vision, and generalized myasthenia gravis, which can involve weakness in various muscle groups, including those responsible for neck movement, chewing, swallowing, speaking, and even breathing. It is important to note that approximately 15% of individuals with MG may only experience ocular symptoms. The presence of AChR antibodies disrupts the normal communication between nerves and muscles by interfering with acetylcholine, the neurotransmitter responsible for transmitting signals at the neuromuscular junction. Specifically, binding antibodies can activate complement pathways, leading to the destruction of the neuromuscular junction and a reduction in the number of available acetylcholine receptors. To diagnose the presence of these antibodies, a venous blood sample is collected, and a quantitative radioimmunoassay is performed. A positive result for AChR binding antibodies, defined as a level greater than 0.4 nmol/L, can confirm the diagnosis of myasthenia gravis in symptomatic patients. However, it is noteworthy that 10%-15% of individuals with MG may not test positive for AChR antibodies and may require further testing for other antibodies, such as muscle-specific kinase (MuSK) antibodies. Binding antibodies are particularly prevalent in patients with generalized myasthenia gravis, making this test a critical component in the diagnostic process.